儿童患者血浆维奈克拉浓度液相色谱串联质谱检测方法的建立及其临床应用研究

    Development and Clinical Application of an LC-MS/MS Method for the Determination of Venetoclax Plasma Concentrations from Pediatric Patients

    • 摘要:
      目的 开发一种儿童患者血浆维奈克拉浓度的液相色谱串联质谱测定方法,对其进行方法学验证以及临床应用。
      方法 血浆样品前处理后,以维奈克拉-d8为内标,选择Eclipse Plus C18 (100 mm×2.1 mm,3.5 μm)色谱柱,以含0.1% 甲酸和2 mmol·L−1乙酸铵的水溶液(A)和含0.1% 甲酸的乙腈溶液(B)为流动相,65%B等度洗脱,流速 0.4 mL·min−1,柱温40 ℃,进样量1 μL,总分析时间2 min。采用正离子电喷雾离子源,多反应监测模式,维奈克拉和维奈克拉-d8的定量和定性离子对分别为m/z 868.30→321.15、m/z 868.30→177.10和m/z 876.25→329.25、m/z 876.25→177.25。对方法进行专属性、线性、重复性、基质效应、精密度、准确度、稳定性、稀释效应、残留效应、加样回收率考察。检测7例急性髓系白血病(acute myeloid leukemia,AML)患儿临床标本。
      结果 成功建立儿童患者维奈克拉血浆浓度液相色谱串联质谱检测方法,线性范围为0.05~5.00 mg·L−1(r=0.999 6),定量下限为0.05 mg·L−1。在不同质控水平下,批内、批间精密度为1.77%~6.25%,准确度为96.17%~106.24%。正常血浆基质、15%高脂血浆基质、5%溶血血浆基质不影响维奈克拉血药浓度检测。血浆样品进样器放置24 h、室温放置24 h、反复冻融3次均稳定。残留不影响维奈克拉的定量分析。7例AML患儿14份临床标本的谷浓度C0为0.126~1.620 mg·L−1,峰浓度C6为0.791~2.639 mg·L−1。
      结论 本研究建立的血浆维奈克拉浓度液相色谱串联质谱检测方法分析性能符合要求,前处理简单,仅需血浆20 μL,可用于儿童患者维奈克拉药动学研究和日常血药浓度检测。

       

      Abstract:
      OBJECTIVE To develop a liquid chromatography-tandem mass spectrometry(LC-MS/MS) method for detecting venetoclax plasma concentrations in pediatric patients and to apply it in clinical practice.
      METHODS Venetoclax plasma concentrations were determined by LC-MS/MS with venetoclax-d8 adopted as the internal standard after protein precipitation. An Eclipse Plus C18 (100 mm×2.1 mm, 3.5 μm) column was used for separation with a mobile phase consisting of 0.1% formic acid and 2 mmol·L−1 ammonium acetate in water(A) and 0.1% formic acid in acetonitrile(B) at 65% B for isocratic elution. The flow rate was 0.4 mL·min−1, column temperature was 40 °C, injection volume was 1 μL, and total analysis time was 2 min. The electrospray ionization source coupled with positive ion and multiple reaction monitoring mode was applied. The quantitative and qualitative ion pairs were m/z 868.30→321.15, m/z 868.30→177.10 for venetoclax and m/z 876.25→329.25, m/z 876.25→177.25 for venetoclax-d8, respectively. The method was validated for specificity, linearity, repeatability, matrix effect, precision, accuracy, stability, dilution effect, carry-over, and recovery. Plasma samples from 7 pediatric patients with acute myeloid leukemia(AML) treated with venetoclax were determined.
      RESULTS An LC-MS/MS method was successfully developed for quantifying venetoclax concentrations in pediatric plasma samples. The linear range was 0.05−5.00 mg·L−1(r=0.999 6), and the lower limit of quantification was 0.05 mg·L−1. Across all quality control concentrations, intra- and inter-batch precision were between 1.77% and 6.25%, while the assay accuracy ranged from 96.17% to 106.24%. Normal plasma matrix, 15% hyperlipidemic plasma matrix, and 5% hemolysis plasma matrix did not interfere with the determination of venetoclax plasma concentrations. Plasma samples were stable when kept in the autosampler for 24 h, at room temperature for 24 h, and after three freeze-thaw cycles. No carryover effect was observed in the quantitative analysis of venetoclax. A total of 14 plasma samples involving 7 pediatric patients with AML were determined. The trough concentration(C0) of venetoclax ranged from 0.126 to 1.620 mg·L−1, and the peak concentration(C6) ranged from 0.791 to 2.639 mg·L−1.
      CONCLUSION The established LC-MS/MS assay exhibited satisfactory analytical performance that complies with the requirements of the reference method. The pretreatment procedure is simple, requiring only 20 μL of plasma, which is suitable for pediatric venetoclax pharmacokinetic investigations and routine therapeutic drug monitoring.

       

    /

    返回文章
    返回